by the practice as of the date of such visits, the percentage of such admissions that are associated with qualified cancer diagnoses of the individuals. (C) Survivorship measures (i) Survival rates for such individuals who have been diagnosed with stage I through IV breast cancer. (ii) Survival rates for such individuals who have been diagnosed with stage I through IV colorectal cancer. (iii) Survival rates for such individuals who have been diagnosed with stage I through IV lung cancer. (iv) With respect to such individuals who receive chemotherapy treatment from the practice, the percentage of such individuals so treated who receive a survivorship plan not later than 45 days after the completion of the administration of such chemotherapy. (v) With respect to such individuals who receive chemotherapy treatment from the practice, the percentage of such individuals who receive psychological screening. (D) End-of-life care measures (i) The number of times that such an individual receives chemotherapy treatment from the practice within an amount of time specified by the Secretary, in consultation with stakeholders, prior to the death of the individual. (ii) With respect to such individuals who have a stage IV disease and have received treatment for such disease from the practice, the percentage of such individuals so treated who have had a documented end-of-life care conversation with a physician in the practice or another health care provider who is a member of the cancer care team of the practice. (iii) With respect to such an individual who is referred to hospice care by a physician in the practice or a health care provider who is a member of the cancer care team of the practice, regardless of the setting in which such care is furnished, the average number of days that the individual receives hospice care prior to the death of the individual. (iv) With respect to such individuals who die while receiving care from the practice, the percentage of such deceased individuals whose death occurred in an acute care